Lebrikizumab (Ebglyss)
What is lebrikizumab?
Lebrikizumab (Ebglyss) is an injectable biologic medication used in dermatology for moderate-to-severe atopic dermatitis. It is a targeted treatment designed to reduce inflammation and itch in patients whose eczema is not adequately controlled with topical treatment (including topical steroids) alone or when topical therapy is not a good fit.
It is one of the biologic options for eczema and is most relevant for patients whose disease is more widespread, more persistent, or causing major sleep disruption, discomfort, or quality-of-life problems.
How does lebrikizumab work?
Lebrikizumab targets interleukin-13 (IL-13), one of the key inflammatory signals involved in atopic dermatitis. By reducing IL-13 activity, lebrikizumab can help calm inflammation, improve the skin barrier, and reduce itching.
Because it focuses on a specific part of the immune pathway rather than broadly suppressing the immune system, it is often discussed as a more targeted long-term treatment option for eczema.
What are possible side effects of lebrikizumab?
Possible side effects can include:
Eye irritation or conjunctivitis
Injection site reactions
Itching or irritation around the eyes
Upper respiratory symptoms in some patients
Many patients tolerate treatment well, but side effects, eye symptoms, and overall treatment risks should always be reviewed with the prescribing clinician.
How is lebrikizumab used?
Lebrikizumab is given by injection on a schedule directed by your provider. Some patients may be able to self-inject after proper training. The medication is stored in the refrigerator.
Your provider may review prior treatments, vaccination status, and overall eczema severity before starting therapy. In practice, this medication is often considered for patients who have already tried multiple topical treatments or who need something more durable for ongoing control.